Parkinson’s
disease
(PD)
is
the
second
most
common
neurodegenerative
globally,
and
there
currently
no
effective
treatment
for
this
condition.
Excessive
accumulation
of
reactive
oxygen
species
(ROS)
neuroinflammation
are
major
contributors
to
PD
pathogenesis.
Herein,
ultrasmall
nanoscale
coordination
polymers
(NCPs)
coordinated
by
ferric
ions
natural
product
curcumin
(Cur)
were
exploited,
showing
efficient
neuroprotection
scavenging
excessive
radicals
suppressing
neuroinflammation.
In
a
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced
mouse
model,
such
Fe-Cur
NCPs
with
prolonged
blood
circulation
BBB
traversing
capability
could
effectively
alleviate
oxidative
stress,
mitochondrial
dysfunction,
inflammatory
condition
in
midbrain
striatum
reduce
symptoms.
Thus,
study
puts
forth
unique
type
therapeutics-based
that
be
used
safe
potential
clinical
translation.
Current Pharmaceutical Design,
Год журнала:
2024,
Номер
30(19), С. 1459 - 1471
Опубликована: Апрель 15, 2024
Neurological
disorders
impose
a
significant
burden
on
individuals,
leading
to
disabilities
and
reduced
quality
of
life.
However,
recent
years
have
witnessed
remarkable
advancements
in
pharmaceutical
interventions
aimed
at
treating
these
disorders.
This
review
article
aims
provide
an
overview
the
latest
innovations
breakthroughs
neurological
disorder
treatment,
with
specific
focus
key
therapeutic
areas
such
as
Alzheimer's
disease,
Parkinson's
multiple
sclerosis,
epilepsy,
stroke.
explores
emerging
trends
drug
development,
including
identification
novel
targets,
development
innovative
delivery
systems,
application
personalized
medicine
approaches.
Furthermore,
it
highlights
integration
advanced
technologies
gene
therapy,
optogenetics,
neurostimulation
techniques.
These
hold
promise
for
precise
modulation
neural
circuits,
restoration
neuronal
function,
even
disease
modification.
While
offer
hopeful
prospects
more
effective
tailored
treatments,
challenges
need
improved
diagnostic
tools,
new
targets
intervention,
optimization
methods
will
remain.
By
addressing
continuing
invest
research
collaboration,
we
can
revolutionize
treatment
significantly
enhance
lives
those
affected
by
conditions.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Май 13, 2024
Abstract
The
use
of
nanomaterials
in
medicine
offers
multiple
opportunities
to
address
neurodegenerative
disorders
such
as
Alzheimer's
and
Parkinson's
disease.
These
diseases
are
a
significant
burden
for
society
the
health
system,
affecting
millions
people
worldwide
without
sensitive
selective
diagnostic
methodologies
or
effective
treatments
stop
their
progression.
In
this
sense,
gold
nanoparticles
is
promising
tool
due
unique
properties
at
nanometric
level.
They
can
be
functionalized
with
specific
molecules
selectively
target
pathological
proteins
Tau
α-synuclein
Alzheimer’s
Parkinson’s
disease,
respectively.
Additionally,
these
used
biomarkers,
wherein
play
key
role
enhancing
signal,
even
low
concentrations
present
biological
samples
blood
cerebrospinal
fluid,
thus
enabling
an
early
accurate
diagnosis.
On
other
hand,
act
drug
delivery
platforms,
bringing
therapeutic
agents
directly
into
brain,
improving
treatment
efficiency
precision,
reducing
side
effects
healthy
tissues.
However,
despite
exciting
potential
nanoparticles,
it
crucial
challenges
issues
associated
medical
field
before
they
widely
applied
clinical
settings.
It
critical
ensure
safety
biocompatibility
context
central
nervous
system.
Therefore,
rigorous
preclinical
studies
needed
assess
efficacy
feasibility
strategies
patients.
Since
there
scarce
sometimes
contradictory
literature
about
context,
main
aim
review
discuss
analyze
current
state-of-the-art
relation
delivery,
diagnosis,
therapy
well
recent
research
preclinical,
clinical,
emerging
areas.
Graphical
As
a
form
of
dementia,
Alzheimer's
disease
(AD)
suffers
from
no
efficacious
cure,
yet
AD
treatment
is
still
imperative,
as
it
ameliorates
the
symptoms
or
prevents
deteriorating
maintains
current
status
to
longest
extent.
The
human
brain
most
sensitive
and
complex
organ
in
body,
which
protected
by
blood-brain
barrier
(BBB).
This
induces
difficulty
curing
drugs
nanomaterials
that
are
much
inhibited
reaching
lesion
site.
Thus,
BBB
crossing
capability
drug
delivery
system
remains
significant
challenge
development
neurological
therapeutics.
Fortunately,
nano-enabled
systems
possess
promising
potential
achieve
multifunctional
diagnostics/therapeutics
against
various
targets
owing
their
intriguing
advantages
nanocarriers,
including
easy
multifunctionalization
on
surfaces,
high
surface-to-volume
ratio
with
large
payloads,
ability
cross
BBB,
making
them
capable
conquering
limitations
conventional
candidates.
review,
focuses
diagnosis
treatment,
will
provide
an
insightful
vision
conducive
AD-related
nanomaterials.
Parkinson’s
disease
(PD)
is
the
second
most
common
neurodegenerative
globally,
and
there
currently
no
effective
treatment
for
this
condition.
Excessive
accumulation
of
reactive
oxygen
species
(ROS)
neuroinflammation
are
major
contributors
to
PD
pathogenesis.
Herein,
ultrasmall
nanoscale
coordination
polymers
(NCPs)
coordinated
by
ferric
ions
natural
product
curcumin
(Cur)
were
exploited,
showing
efficient
neuroprotection
scavenging
excessive
radicals
suppressing
neuroinflammation.
In
a
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced
mouse
model,
such
Fe-Cur
NCPs
with
prolonged
blood
circulation
BBB
traversing
capability
could
effectively
alleviate
oxidative
stress,
mitochondrial
dysfunction,
inflammatory
condition
in
midbrain
striatum
reduce
symptoms.
Thus,
study
puts
forth
unique
type
therapeutics-based
that
be
used
safe
potential
clinical
translation.
